Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 2/20 | 0.49 |
| ▸ | CPT1A | P50416 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561797 | 0.80 | NR1H3 (0.56) | PKMCYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1633443 | 0.80 | NPC1 (0.53) | PKMCYP2C9KMT2AMEN1ALDH1A1 | |
| SCHEMBL12354747 | 0.74 | PKM (1.00) | PKMKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28823982 | 0.73 | RORC (0.66) | CYP2C9KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31750691 | 0.72 | CYP2C9 (0.71) | CYP2C9KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL34475705 | 0.72 | CYP2C9 (0.71) | CYP2C9KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12354740 | 0.71 | PKM (1.00) | PKMKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24286266 | 0.70 | PKM (0.57) | PKMCYP2C9KMT2ACPT2CPT1A | |
| SCHEMBL18581887 | 0.70 | CYP2C9 (0.66) | PKMCYP2C9KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL753865 | 0.70 | CPT1A (0.79) | CYP2C9CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | PKM 1211/4885CYP2C9 3169/4885KMT2A 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.